Alok Kanti, president and CEO of Bayer Canada, draws upon his 27 years of international experience with Bayer to discuss the strategic significance of the Canadian affiliate to Bayer’s global operations, the challenges and opportunities he sees for industry-government collaboration, and the need for the country to promote a more coherent life sciences innovation strategy.
As a globally established life sciences company, what is the strategic significance of the Canadian affiliate?
"Canada offers relatively transparent institutions, a demand for innovation, and leading clinical practice and expertise."
